Related Experiment Video

Updated: Mar 6, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context

Alexander D Le1, Saeed K Alzghari2, Gary W Jean2

  • 1Department of Immunotherapeutics and Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene.

Therapeutics and Clinical Risk Management
|March 7, 2017
PubMed

Insights

Nivolumab, an immune checkpoint inhibitor, shows promise for advanced non-small cell lung cancer (NSCLC) treatment, offering durable remissions. This review examines its clinical evidence, role alongside other targeted therapies, and impact on patient quality of life and health economics.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) treatment traditionally involves surgery, chemotherapy, and radiation.
  • Advances in NSCLC biology and immunology have led to targeted therapies.
  • Immune checkpoint inhibitors, like nivolumab, show potential for durable remissions in advanced NSCLC.

Purpose of the Study:

  • To review the clinical evidence for nivolumab in NSCLC treatment.
  • To clarify nivolumab's role among existing targeted therapies for NSCLC.
  • To discuss the impact of nivolumab on patient quality of life and health economics.

Main Methods:

  • Literature review of clinical trials and studies on nivolumab for NSCLC.
  • Analysis of nivolumab's efficacy, safety, and mechanism of action.
  • Evaluation of health economic data and quality of life assessments related to nivolumab.

Main Results:

  • Nivolumab has demonstrated remarkable durable remissions in a subset of advanced NSCLC patients.
  • The review clarifies nivolumab's position relative to other targeted NSCLC therapies.
  • Impact on patient quality of life and health economics is discussed.

Conclusions:

  • Nivolumab represents a significant advancement in NSCLC treatment, offering a new therapeutic option.
  • Understanding nivolumab's role is crucial for optimizing NSCLC management.
  • Further research into quality of life and health economics will guide its broader implementation.
Keywords:
immune checkpointlung cancernivolumabtargeted therapy

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K